Amgen PT Raised to $132.00 at Brean Capital (AMGN)
Analysts at Brean Capital upped their price target on shares of Amgen (NASDAQ:AMGN) from $119.00 to $132.00 in a research report issued to clients and investors on Wednesday, AnalystRatingsNetwork reports. The firm currently has a “buy” rating on the stock. Brean Capital’s target price would suggest a potential upside of 13.48% from the stock’s previous close.
AMGN has been the subject of a number of other recent research reports. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Amgen in a research note to investors on Tuesday, October 22nd. Separately, analysts at Leerink Swann reiterated a “market perform” rating on shares of Amgen in a research note to investors on Wednesday, October 2nd. They now have a $128.00 price target on the stock. Finally, analysts at BMO Capital Markets raised their price target on shares of Amgen from $108.00 to $116.00 in a research note to investors on Tuesday, September 24th. They now have a “market perform” rating on the stock. Eleven research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $117.96.
Amgen (NASDAQ:AMGN) traded up 0.10% during mid-day trading on Wednesday, hitting $116.32. 2,005,042 shares of the company’s stock traded hands. Amgen has a one year low of $80.60 and a one year high of $114.95. The stock has a 50-day moving average of $109.2 and a 200-day moving average of $103.3. The company has a market cap of $87.705 billion and a price-to-earnings ratio of 18.43.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, October 22nd. The company reported $1.94 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.78 by $0.16. The company had revenue of $4.75 billion for the quarter, compared to the consensus estimate of $4.60 billion. During the same quarter last year, the company posted $1.67 earnings per share. Amgen’s revenue was up 9.9% compared to the same quarter last year. On average, analysts predict that Amgen will post $7.45 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Friday, December 6th. Investors of record on Thursday, November 14th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 1.62%. The ex-dividend date of this dividend is Tuesday, November 12th.
Amgen Inc is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.